Tab Application Banner
  • Users Online: 876
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2007  |  Volume : 2  |  Issue : 1  |  Page : 23-30

Management of interstitial lung disease in scleroderma

Department of Medicine, All India Institute of Medical sciences, New Delhi, India

Correspondence Address:
R Gupta
Department of Medicine, All India Institute of Medical sciences, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Interstitial lung disease (ILD) is now the major cause of mortality in patients with systemic sclerosis (scleroderma) after dramatic reduction in death caused by scleroderma renal crisis, because of the regular use of angiotensin- converting enzyme inhibitors. Treatment of ILD in scleroderma has been somewhat haphazard and treatment protocol often been borrowed from the experience gained from treating ILD of unknown aetiology. The purpose of this review is to outline recent advances and current concepts regarding the management of these ILDs.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded41    
    Comments [Add]    

Recommend this journal